Frontier Bio, an anti-AIDS drug research and development company, went public today

According to the exchange announcement, "Anti-Ai leading shares" frontier biopharmaceiter (Nanjing) Co., Ltd. ("frontier biology") today in the Shanghai Stock Exchange Branch of the board listed.
issue price is 20.50 yuan per share, the number of shares issued is 89.96 million shares.
public information shows that Frontier Bio is a China-based, global-oriented, internationally competitive and innovative biopharmaceutical company dedicated to research, development, production and marketing of innovative drugs for major unseeded clinical needs.
the company's unique cutting-edge strategic layout has made it highly visible in the anti-AIDS space before it went public.
In May 2018, the first product independently developed by Frontier Biology, Ai Corning, became china's first original anti-AIDS drug, and the world's first long-acting HIV fusion inhibitor, effectively breaking the monopoly of foreign pharmaceutical companies to fight AIDS new drugs.
Photo Source: Frontier Bio-Official Website Ai Corning has a new molecular mechanism, is effective against the main prevalence of HIV-1 virus and drug-resistant viruses, and has a low frequency of drug use (once a week), high resistance barrier, high safety, small side effects and other advantages, combined with other anti-AIDS drug treatment, can quickly and powerfully suppress the virus and improve immunity.
In addition to the original anti-AIDS drugs, Frontier Bio has two new drugs in the U.S. Phase II clinical phase, patented (or patented), with clear clinical efficacy - the new permeable analgesic patch AB001 and the "Aykonin-3BNC117 combination therapy", which has been granted fast-track status by the FDA for multidruproidation, HIV maintenance, HIV immunotherapy, and even HIV prevention.
if the two drugs can be successfully developed and marketed, it will provide a solid guarantee for the company's continued and stable development.
Bioaversing Source: Biological Exploration Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mays Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here